GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE6861 Query DataSets for GSE6861
Status Public on Nov 23, 2007
Title Prediction of breast cancer pathological complete response to anthracycline/taxane chemotherapy.
Organism Homo sapiens
Experiment type Expression profiling by array
Summary EORTC 10994 phase III breast cancer clinical trial comparing FEC (5-fluorouracil, cyclophosphamide, epirubicin) with ET (epirubicin, docetaxel). 161 needle biopsies of locally advanced or large operable breast tumours were hybridised to Affymetrix X3P chips. The array data from the ER negative tumours (28/65 pathological CR in the FEC arm, 27/59 pathological CR in the ET arm) were used to validate the cell line-based chemotherapy response predictors developed by the Potti/Nevins group at Duke University (doi:10.1038/nm1491).
Keywords: Tumour profiling
Overall design We analyzed 161 arrays of breast carcinoma.
Contributor(s) Farmer P, Bonnefoi H, Iggo R
Citation(s) 18024211, 25601208
Submission date Jan 25, 2007
Last update date Jun 06, 2022
Contact name Richard Iggo
Phone +33 5 56 33 04 23
Fax +33 5 56 33 32 06
Organization name University of Bordeaux
Department Bergonie Cancer Institute
Street address 229 cours de l'Argonne
City Bordeaux
ZIP/Postal code 33076
Country France
Platforms (1)
GPL1352 [U133_X3P] Affymetrix Human X3P Array
Samples (161)
GSM158188 HB01bis
GSM158189 HB02bis
GSM158190 HB03bis
BioProject PRJNA99107

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE6861_RAW.tar 1.4 Gb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap